Estee Lauder FY 1996 third quarter net income up 37.6% to $28.2 mil. on sales of $763.9 mil..
This article was originally published in The Rose Sheet
Executive Summary
ESTEE LAUDER NET INCOME UP 37.6% TO $28.2 MIL. IN THIRD QUARTER FY 1996 (ended March 31) on sales of $763.9 mil., an 8.7% increase over the prior year, the firm announced April 30. Excluding the impact of foreign currency, net sales grew 10%. The company highlighted the performance of its U.S. divisions, each of which "achieved double-digit retail sales growth during the quarter" as well as "market share gains." Estee Lauder also cited new product introductions and the "continued success" of its established brands as reasons behind the sales growth
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.